Abstract 1556P
Background
Osemitamab, a humanized Claudin18.2 monoclonal antibody with enhanced antibody-dependent cellular cytotoxicity (ADCC) via improved binding affinity and reduced fucosylation, is being developed to treat metastatic gastric/gastroesophageal junction (G/GEJ) adenocarcinoma. Pharmacokinetics (PK), pharmacodynamics (PD) and exposure-response (ER) relationship of Osemitamab were evaluated in two phase I/IIa studies.
Methods
Osemitamab was administrated as monotherapy or in combination with standard of care (SOC) in patients. PK profiles of osemitamab were determined using non-compartmental analysis and population PK. The ADCC capacity of circulating osemitamab was tested in a subset of patients who received 3-10mg/kg Q3W. Relationships between PK and objective response rate (ORR) and safety were explored.
Results
A total of 2401 PK data were obtained from 248 patients from two clinical trials. Similar PK was observed between the US and Chinese patients. PK is dose proportional between 0.3 to 15 mg/kg. A two-compartment model with first-order elimination described the PK profile of osemitamab. Clearance (CL) was affected by body weight and gastrectomy history. Model simulated steady state trough concentration will achieve in vitro ADCC assay EC95 and in vivo MKN45-CLDN18.2 tumor growth inhibition model EC50 in most subjects following 6mg/kg Q3W and 4mg/kg Q2W. ADA incidence is less than 10%. Serum ADCC response remained at ∼ 50% of the maximum lysis up to 21 days following osemitamab 6 mg/kg Q3W. Anti-tumor activity data from 58 patients with 1L G/GEJ adenocarcinoma treated with osemitamab and capecitabine and oxaliplatin (CAPOX) showed patients with average concentration in 56 days above 24 μg/mL tended to have a better ORR. Grade 2+ nausea/vomiting are found to be associated with osemitamab exposure; however, simulations demonstrated the proportion of patients that developed Grade 2+ nausea or vomiting by 6 months were just slightly higher (< 10% in difference) following 6 mg/kg Q3W than 3 mg/kg Q3W.
Conclusions
Osemitamab at 6mg/kg Q3W or 4mg/kg Q2W are predicted to have favorable PK/PD/safety profiles and might be associated with better ORR in combination with SOC compared to the lower doses.
Clinical trial identification
NCT04396821, NCT04495296.
Editorial acknowledgement
Legal entity responsible for the study
Suzhou Transcenta Therapeutics Co., Ltd.
Funding
Suzhou Transcenta Therapeutics Co., Ltd.
Disclosure
J. Yao; D. Chen; X. Lin; C. Qi; Z. Xia; L. Zhang; S. Yu; C. Germa; Financial Interests, Personal, Full or part-time Employment: Transcenta. All other authors have declared no conflicts of interest.
Resources from the same session
1489P - To investigate the differences in efficacy between immunotherapy and combined immunotherapy in elderly patients with non-small cell lung cancer
Presenter: Ye Mao
Session: Poster session 21
1490P - Removal of TNF-Rs frees TNF-α’s anticancer activity alone or in combination chemo- or immunotherapy in advanced NSCLC
Presenter: Mustafa Bozkurt
Session: Poster session 21
1491P - PD-L1 TPS ≥50% predicts durable response after discontinuing immune checkpoint inhibitors in metastatic non-small cell lung cancer patients
Presenter: Jeongmin Seo
Session: Poster session 21
1493P - A phase II, multi-center, open-label, dose-optimization study evaluating telomere targeting agent THIO sequenced with cemiplimab in patients with advanced NSCLC: Preliminary results
Presenter: Tomasz Jankowski
Session: Poster session 21
1495P - Cemiplimab plus chemotherapy versus chemotherapy in non-small cell lung cancer with PD-L1 ≥1%: EMPOWER-Lung 3 results
Presenter: Ana Baramidze
Session: Poster session 21
1496P - Higher levels of CSF-1 support resistance to immune checkpoint inhibitors in advanced non-small cell lung cancer
Presenter: Paul Takam Kamga
Session: Poster session 21
1497P - Gut microbiome is associated with the clinical response to anti-PD-1 based immunotherapy in untreated advanced non-small-cell lung cancer
Presenter: Yawen Bin
Session: Poster session 21